Prothena | PRTA - Net Income


Prothena reported $-36.54M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Akebia Therapeutics USD 6.11M 28.92M Mar/2025
ALKERMES USD 82.76M 4.34M Sep/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Exelixis USD 193.58M 8.73M Sep/2025
Immunic USD -24.37M 2.99M Sep/2024
Incyte USD 299.28M 124.89M Dec/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
MacroGenics USD 16.82M 53.07M Sep/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Prothena USD -36.54M 89.23M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025
Xoma USD -17.24M 33.23M Sep/2024